28 Feb 2024
Job Information
- Organisation/Company
INSERM- Department
Departement des Ressources Humaines- Research Field
Medical sciences » Cancer research- Researcher Profile
Established Researcher (R3)
Leading Researcher (R4)- Country
France- Application Deadline
2 Apr 2024 - 17:00 (Europe/Paris)- Type of Contract
Permanent- Job Status
Full-time- Hours Per Week
35- Offer Starting Date
1 Oct 2024- Is the job funded through the EU Research Framework Programme?
Not funded by an EU programme- Is the Job related to staff position within a Research Infrastructure?
No
Offer Description
The Inserm chair recruitments opened to Inserm are intended for researchers with strong potential to manage and lead research teams and participate in national, European or international projects.
This recruitment, based on research and teaching projects, is aimed at researchers with a doctorate or equivalent and a first post-doctoral experience. The position is offered on a fixed-term contract (CDD) with a view to tenure in the Inserm Research Directors personnel at the end of the contract.
Strategy of the host institution :
The epitranscriptome is an emerging field with strong clinical potential. Over the last years, chemical modifications of RNA have been identified as a new epigenetic variable, involved in major biological functions and in a large panel of human pathologies including cancers.
Preserving its international visibility in oncology is among the priorities of INSERM and recruiting candidates with high potential in close coordination with its Research Institutes and universities enables to precisely define the priorities of future renewals, site by site.
The INSERM chair on epitranscriptomics at the IRCM (Institute under joint supervision of INSERM, Université de Montpellier and ICM, Institut du Cancer de Montpellier) will strengthen the leadership of the Montpellier campus in the field of oncology. The recruited researcher will develop a very innovative fundamental project with clear clinical perspectives in the field of cancer epitranscriptomics. This project will rely on original platforms and clinical collaborations in which significant financial resources have been invested. The recruited researcher will have the ambition to propose diagnostic, prognostic and therapeutic innovations for the benefit of patients. She/he will also likely bring numerous developments and collaborations with the industrial world.
Finally, support from INSERM for this project will converge with that provided by the Université de Montpellier (through I-Site Muse) and the ICM (SIRIC Montpellier Cancer) and will reinforce their successful joint supervision of the IRCM.
Strategy of the host laboratory :
In barely 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM, www.ircm.fr , INSERM, Université de Montpellier, ICM) has succeeded in raising its research to the highest international level in the field of fundamental and applied cancer research, carried out in close collaboration with the clinical departments of the Montpellier Cancer Center (ICM: l'Institut du Cancer de Montpellier ), and industrial partners. Under the joint supervision of Inserm, ICM and University of Montpellier, the IRCM brings together more than 250 people, researchers, clinicians, technicians and students, organized in 17 research teams that rely on high-performance technical platforms and competent support services. Facing a highly competitive and rapidly evolving field of research, the IRCM promotes technology development, innovation and tight collaborations between clinicians and researchers in order to accelerate clinical breakthroughs transfer to the patient. Over the last decade, the IRCM has launched several international calls to recruit junior emerging teams.
As an INSERM chair, IRCM wishes to recruit a future leader in cancer epitranscriptomics. This recruitment will benefit and reinforce the strong involvement of IRCM in the field: in Montpellier, with the “SMART” consortium, a pluridisciplinary research consortium on epitranscriptomics, the SIRIC ENERGY , FHU EVOCAN 2 and IHU « IMMUN4CURE », programs dedicated to translational research in cancer and in autoimmune diseases, resp.; at the national level, with the GDR "ARN thérapeutique " and at the European level, the COST Action TRANSLACORE (Translational Control in Cancer).
Summary of the scientific project :
To date, more than 100 RNA modifications have been identified. This complex and dynamic combinatorial process regulates all aspects of RNA metabolism and shapes cell phenotype in real time. An increasing number of these chemical modifications are associated with human pathologies and enzymes regulating these pathways show mutations in neurological, developmental, metabolic, cardiovascular diseases and cancers. Then the growing interest in RNAs is not limited to their functional role, but also to the prospects they offer for personalized medicine: disease diagnosis and therapeutic management. Scientific and technical issues remain to be addressed to identify novel RNA modifications, understand their regulations and elucidate their biological functions. This knowledge is needed for the development of innovative diagnostic, pronostic or therapeutic strategies that specifically target these processes.
The recruited researcher will address these issues, aiming at identifying and characterizing RNA marks associated with cancer progression and adaptation. She/he will benefit on multidisciplinary scientific expertise and cutting-edge equipments and approaches available within the IRCM, and on high-level biobanks and clinical services at the ICM and Montpellier University Hospital, allowing access to state-of-art mass spectrometry analysis of patient samples (targeted proteomics and epitranscriptomics) associated with bioinformatics and machine learning developments. In addition, the “SMART” consortium involving chemists represents a unique opportunity to rapidly develop tailored inhibitors for therapeutic targets.
Summary of the teaching project :
The University of Montpellier supports the implementation of a scientific project in the field of cancer epitranscriptomics at the IRCM through a "starting grant" (junior chair) from its I-Site MUSE. This position comes with a small teaching load (28h of lectures) within the Biology and Health Master's program, more specifically within the "Cancer Biology" course in English followed by students from the faculties of Science, Pharmacy and Medicine, offering training in biology and bioinformatics and covering from the basics of molecular biology of cancer to new anti-tumor therapy.
National Research Agency package : 200K€
Other package : Co-funding (e-SITE MUSE): 50-100k€
Remuneration : 3500-5000e monthly according to research experience
Requirements
- Research Field
- Medical sciences » Cancer research
- Education Level
- PhD or equivalent
Additional Information
Selection process
It is expected the recruited researcher to become rapidly a group leader in the GAD team. So the candidate should demonstrate ability to supervise Ph.D students, post-doctoral fellow and technical support staff. She/he should have the capacity to obtain competitive funding to manage her/his group.
Successful candidates are chosen by a selection commission composed of six to ten members, the majority of whom are specialists in the fields of research concerned.
The commission carries out an initial examination of the applications, focused in particular on candidate experience and skills relative to the research and teaching project presented above. A shortlist of candidates is then selected for interview.
Only candidates selected by the selection committee on the basis of their applications will be invited to interview.
The interviews are followed by a deliberation during which selection commission will discuss the quality, originality and, where appropriate, the interdisciplinarity of the research and teaching projects presented by the candidates, their motivation and their scientific and teaching supervision capacity.
Additional comments
Applications can be submitted online at EVA .
Deadline application: April 2, 2024
It is imperative to contact the laboratory corresponding to the Chair you have applied for in order to build the project with them.
Position also open to 'Bénéficiaires de l'Obligation d'Emploi' (disabled persons), as defined in article 27 of law no. 84-16 of January 11, 1984 on statutory provisions for the civil service.
- Website for additional job details
https://eva3-accueil.inserm.fr/sites/eva/chaires/2024/Pages/default.aspx
Work Location(s)
- Number of offers available
- 1
- Company/Institute
- Inserm U1194 - Institut de recherche en Cancérologie de Montpellier (IRCM)
- Country
- France
- City
- Montpellier
- Geofield
Where to apply
- Website
https://eva3-accueil.inserm.fr/sites/eva/chaires/2024/Pages/default.aspx
Contact
- City
Paris- Website
https://www.ircm.fr/- Street
101 rue de Tolbiac - 75654 Paris Cedex 13
[email protected]
[email protected]
STATUS: EXPIRED